Isentress (raltegravir) is a new class of anti-retroviral for the treatment of HIV.

Isentress is indicated in combination with other anti-retrovirals for treatment-experienced adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy


Raltegravir is an integrase inhibitor that inhibits the catalytic activity of integrase, an HIV-encoded enzyme required for viral replication.

Integrase is responsible for inserting the viral DNA into the DNA of the host cell. Inhibition of this enzyme prevents production of new infectious viral particles and further infection of other cells, and results in a reduction in the viral load.

View Isentress drug record

Further information: MSD

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases